The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

AAPP 2026
American Academy of Psychiatric Pharmacists
April 19th – 22nd 2026, Seattle, WA
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Schizophrenia
POSTER
Safety and Efficacy of Aripiprazole Lauroxil in an Outpatient Setting After Initiation During Hospitalization for an Acute Exacerbation of Schizophrenia
AUTHOR(S)

Peter J. Weiden, MD1; Jelena Kunovac, MD, MS2-4; Shifang Liu, PhD5; Daniel J. Kim, PhD5; James A. McGrory, PhD5

View poster
Schizophrenia
Bipolar Disorder
Schizophrenia
POSTER
Olanzapine and Samidorphan in Adults With Schizophrenia or Bipolar I Disorder: Updated Review of Clinical Data
AUTHOR(S)

Leslie Citrome, MD, MPH,1 Christoph U. Correll, MD,2-6 Roger S. McIntyre, MD,7 Mark S. Todtenkopf, PhD,8 Christina Arevalo, MS,8 James A. McGrory, PhD,8 David McDonnell, MD9

View poster
Bipolar Disorder
Schizophrenia
Schizophrenia
POSTER
Inpatient Initiation of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil for the Treatment of Acute Exacerbations of Schizophrenia
AUTHOR(S)

Peter J. Weiden, MD1; Jelena Kunovac, MD, MS2-4; Shifang Liu, PhD5; Daniel J. Kim, PhD5; James A. McGrory, PhD5

View poster
Schizophrenia
Bipolar Disorder
Schizophrenia
POSTER
Real-World Comparison of Olanzapine/Samidorphan vs Olanzapine: An Assessment of Treatment Patterns and Acute Care Events Among Patients With Schizophrenia or Bipolar I Disorder
AUTHOR(S)

Hemangi R. Panchmatia, MSc,1 Rakesh Jain, MD, MPH,2 Alejandro G. Hughes, MPH,3 Michael J. Doane, PhD,1 Craig Chepke, MD,4,5 Andrew J. Cutler, MD6,7

View poster
Bipolar Disorder
Schizophrenia
Bipolar Disorder
Schizophrenia
POSTER
Real-World Impact of Olanzapine and Samidorphan on Rates of Relapse Among Young Adults With Schizophrenia or Bipolar I Disorder
AUTHOR(S)

Andrew J. Cutler, MD,1,2 Hemangi R. Panchmatia, MSc,3 Alejandro G. Hughes, MPH,4 Michael J. Doane, PhD,3 Hara E. Oyedeji, DNP, PMHNP-BC,5 Rakesh Jain, MD6

View poster
Bipolar Disorder
Schizophrenia